<code id='234065DF71'></code><style id='234065DF71'></style>
    • <acronym id='234065DF71'></acronym>
      <center id='234065DF71'><center id='234065DF71'><tfoot id='234065DF71'></tfoot></center><abbr id='234065DF71'><dir id='234065DF71'><tfoot id='234065DF71'></tfoot><noframes id='234065DF71'>

    • <optgroup id='234065DF71'><strike id='234065DF71'><sup id='234065DF71'></sup></strike><code id='234065DF71'></code></optgroup>
        1. <b id='234065DF71'><label id='234065DF71'><select id='234065DF71'><dt id='234065DF71'><span id='234065DF71'></span></dt></select></label></b><u id='234065DF71'></u>
          <i id='234065DF71'><strike id='234065DF71'><tt id='234065DF71'><pre id='234065DF71'></pre></tt></strike></i>

          Home / entertainment / Wikipedia

          Wikipedia


          Wikipedia

          author:knowledge    Page View:6778
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In